QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 23 February 2023Portfolio NewsPrilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study
- 8 February 2023Portfolio NewsNimbus Therapeutics Announces Closing of Takeda's Acquisition of TYK2 Subsidiary
- 24 January 2023SV NewsBritain is losing its chance to become a life sciences superpower
- 16 January 2023SV NewsBritish Patient Capital and Mubadala Invest in SV Biotech Crossover Opportunities Fund
- 9 January 2023Portfolio NewsImbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction
- 26 December 2022Portfolio NewsWhy a lucky few may help the rest of us beat disease
- 20 December 2022Portfolio NewsMestag Therapeutics appoints Prof. Ton Logtenberg as Chair
- 5 December 2022Portfolio NewsNinerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy
- 20 October 2022Portfolio NewsMestag Therapeutics founding investigator Prof. David A. Tuveson elected to US National Academy of Medicine
- 5 October 2022Portfolio NewsCarolyn Bertozzi, repeat biotech founder and launcher of a field, shares in chemistry Nobel win
- 12 September 2022Portfolio NewsNimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology
- 12 September 2022Portfolio NewsAlchemab Therapeutics— Cracking the secrets of protective auto-immunity